Fish Oils in Lupus

Completed

• Conditions: Systemic Lupus Erythematosus (SLE); Musculoskeletal Diseases; Erythematosus

• Registration Number: ISRCTN66445141
• Lead Sponsor: Queen's University of Belfast (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-07-22
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients (adult, either sex) fulfilling American College of Rheumatology (ACR) classification criteria for SLE.

Exclusion Criteria

1. Diabetes mellitus (fasting blood glucose more than 7.8 mmol/l)
2. Hypertension of systolic more than 160 mmHg or diastolic more than 90 mmHg (as determined by the mean of three readings taken on the first visit)
3. Carcinoma (other than superficial skin carcinoma)
4. Significant pulmonary, hepatic or renal disease
5. Typical angina or myocardial infarction
6. Active infectious diseases
7. Use of antihypertensive, oral hypoglycaemic or lipid lowering agent (in the last three months)
8. Cyclophosphamide therapy (due to potential to interfere with acetylcholinesterase)
9. Glucocorticoids equivalent to greater than 10 mg prednisolone
10. All pregnant or lactating women will be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improved nitric oxide bioactivity and reduced superoxide bioactivity.

Secondary Outcome Measures

Name	Time	Method
Improved vascular reactivity and endothelial function, clinical response as measured by Revised activity index of Systemic Lupus Activity Measure (SLAM-R), Systemic Lupus International Collaborating Clinics (SLICC) and British Isles Lupus Assessment Group (BILAG).